Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of an Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
NCT07464314Phase 1Recruiting
- Sponsor
- GSK
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Flu/COVm in influenza and coronavirus disease 2019 (COVID-19) (5 arms), sponsored by GSK. Primary endpoints: Number of Participants with an Increase in Toxicity Grade of Laboratory Value Abnormalities at Day 29, Number of Participants with Solicited Administration Site Adverse Events at Day 7 and 5 more. Started Mar 2026; status: recruiting.
02
Drugs
Flu/COVm
03
Conditions
influenzacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07464314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07464314.